Related Experiment Video
Updated: Sep 18, 2025
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.5K
Bevacizumab in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: A Risk-Stratified Analysis
1Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara 06200, Turkey.
Pharmaceuticals (Basel, Switzerland)
|June 27, 2025
Summary
Bevacizumab improved survival in high-risk platinum-sensitive recurrent ovarian cancer (PSROC) but not low-risk patients. This study stratified PSROC patients to personalize treatment strategies.
Area of Science:
- Oncology
- Gynecologic Oncology
- Cancer Therapeutics
Background:
- Epithelial ovarian cancer (EOC) is a complex disease with varied clinical and molecular features, often diagnosed at advanced stages.
- Platinum-sensitive recurrent ovarian cancer (PSROC) presents treatment challenges due to resistance and recurrence.
- Bevacizumab, an anti-angiogenic agent, is used for PSROC, but its survival impact across risk groups is not fully understood.
Purpose of the Study:
- To compare treatment responses in high- and low-risk groups of patients with PSROC.
- To evaluate the effects of bevacizumab on progression-free survival (PFS) and overall survival (OS) within these risk strata.
- To investigate the relationship between treatment response, recurrence patterns, and survival in PSROC patients.
Main Methods:
- Retrospective study of 174 patients with FIGO stage III/IV EOC treated for PSROC with chemotherapy or chemotherapy plus bevacizumab.
- Patients were stratified into low-risk and high-risk groups based on clinicopathological characteristics.
- Survival analyses (PFS, OS) and adverse events were examined concerning risk groups and bevacizumab use.
Main Results:
- Low-risk patients had significantly longer PFS (13.7 months) and OS (36.5 months) than high-risk patients (PFS 10.8 months, OS 23.5 months).
- In low-risk patients, bevacizumab significantly improved PFS (13.5 vs. 9.7 months) but not OS (39.4 vs. 33.3 months).
- In high-risk patients, bevacizumab significantly improved both PFS (13.9 vs. 8.8 months) and OS (36.5 vs. 23.2 months).
Conclusions:
- This study uniquely evaluates bevacizumab effectiveness in PSROC based on clinical risk groups and recurrence patterns using real-world data.
- Bevacizumab demonstrated significant survival benefits (PFS and OS) in high-risk PSROC patients.
- The findings suggest that risk stratification is crucial for personalizing bevacizumab treatment strategies in PSROC.
Keywords:
bevacizumabcytoreductive surgeryhigh risklocation of recurrencelow riskplatinum sensitiverecurrent epithelial ovarian cancerMore Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:21Cancer Survival Analysis
458
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
458